Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response.

[1]  H. Iwata,et al.  Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer , 2021, BMC Cancer.

[2]  O. Sarig,et al.  Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis , 2021, Experimental dermatology.

[3]  J. Farber,et al.  Bile acids improve psoriasiform dermatitis through inhibition of IL-17A expression and CCL20-CCR6 mediated trafficking of T cells. , 2021, The Journal of investigative dermatology.

[4]  T. Torres,et al.  New Topical Therapies for Psoriasis , 2021, American Journal of Clinical Dermatology.

[5]  B. Smith,et al.  Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. , 2021, Leukemia research.

[6]  G. Tan,et al.  ULK1 Inhibition as a Targeted Therapeutic Strategy for Psoriasis by Regulating Keratinocytes and Their Crosstalk With Neutrophils , 2021, Frontiers in Immunology.

[7]  M. Pellegrini,et al.  IRAK2 has a critical role in promoting feed-forward amplification of epidermal inflammatory responses. , 2021, The Journal of investigative dermatology.

[8]  L. Tsoi,et al.  Dysregulated epigenetic modifications in psoriasis , 2021, Experimental dermatology.

[9]  H. Chung,et al.  Topical Application of MS-275 Decreases the Imiquimod-Induced Hyperproliferative Epidermis and Interleukin-23 Expression in the Upper Dermis of BALB/c Mouse , 2021, Annals of dermatology.

[10]  J. Na,et al.  Histone Deacetylase 1 and Sirtuin 1 Expression in Psoriatic Skin: A Comparison between Guttate and Plaque Psoriasis , 2020, Life.

[11]  W. Ellmeier,et al.  Histone deacetylases as targets in autoimmune and autoinflammatory diseases. , 2020, Advances in immunology.

[12]  P. Jena,et al.  Short-term exposure to a Western diet induces psoriasiform dermatitis by promoting accumulation of IL-17A-producing γδ T cells. , 2020, The Journal of investigative dermatology.

[13]  M. Furue,et al.  Interleukin-17A and Keratinocytes in Psoriasis , 2020, International journal of molecular sciences.

[14]  D. Fairlie,et al.  Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro , 2020, Journal of cellular biochemistry.

[15]  R. Holmdahl,et al.  Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. , 2019, Journal of autoimmunity.

[16]  L. Skov,et al.  Localization of treatment‐resistant areas in patients with psoriasis on biologics , 2019, The British journal of dermatology.

[17]  Xiaotian Chen,et al.  Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. , 2018, Inflammatory bowel diseases.

[18]  W. Boehncke,et al.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond , 2018, Front. Immunol..

[19]  J. Bagel,et al.  A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy. , 2018, Journal of drugs in dermatology : JDD.

[20]  W. Ellmeier,et al.  Histone deacetylase function in CD4+ T cells , 2018, Nature Reviews Immunology.

[21]  C. Albanesi,et al.  The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis , 2018, Front. Immunol..

[22]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[23]  C. Zenobia,et al.  Basic biology and role of interleukin-17 in immunity and inflammation. , 2015, Periodontology 2000.

[24]  B. Gibson,et al.  SIRT1 deacetylates RORγt and enhances Th17 cell generation , 2015, The Journal of experimental medicine.

[25]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[26]  B. Malissen,et al.  IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. , 2014, The Journal of investigative dermatology.

[27]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[28]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[29]  Ido D. Weiss,et al.  CCR6 is required for epidermal trafficking of γδ T cells in an IL-23-induced model of psoriasiform dermatitis , 2012, The Journal of investigative dermatology.

[30]  B. Becher,et al.  Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. , 2012, The Journal of clinical investigation.

[31]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[32]  Ming Zhao,et al.  Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. , 2011, European journal of dermatology : EJD.

[33]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[34]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.